People
Acticor Biotech Announces Names Munoz as Board Chairman and Binay and Pletan as General Managers
16 June 2021 - - French biotechnology company Acticor Biotech has appointed Alain Munoz as chairman of the board of directors and Mrs Sophie Binay and Mr Yannick Pletan as general managers, the company said.

Mrs Sophie Binay and Mr Yannick Pletan will continue to assume their current functions in the company as CSO and CMO respectively.

Mr Alain Munoz, MD, PhD, new chairman of the Acticor board of directors, is a physician, qualified in cardiology and intensive care.

He has over 30 years of experience in the industry at senior management level. He served as SVP for international development in the Sanofi Group and in the pharmaceutical division of Fournier Laboratories.

He has been a member of the Scientific Committee of the French drug agency, chairman of the board of Hybrigenics SA and Novagali Pharma SA (TODAY SANTEN).

He presently serves on the scientific advisory board of Valneva SA and in is an independent board member of Amryt Pharma plc, Auris Medical Holding AG and Zealand Pharma A/S.

Sophie Binay, PhD, nominated as general manager and CSO of Acticor Biotech, has over 20 years' experience in start-ups and mid-size companies within the biotechnology areas.

She has expertise in oncology, immunology and virology. Sophie has managed numbers of innovative R and D projects from the proof-of-concept to early clinical development.

In her previous positions, Sophie was vice-president Research and Early Clinical Development at PEP-Therapy, responsible for nonclinical R and D activities at InnaVirVax, Head of translational programs in oncology at Gustave Roussy Cancer Center and R and D director at Onxeo (former Bioalliance Pharma).

Yannick is an expert in clinical development within the pharmaceutical industry. He previously held leadership positions at Roche, Pfizer, Sanofi and Pierre Fabre.

Before joining Acticor Biotech, he served as head of the Medical Division and was a board member of the Foundation at Roche France and member of the Global Medical Affairs Committee at Hoffman La Roche Ltd (Switzerland).

Prior to these activities, he was also vice-president, head of Medical and Scientific Division and board member of the Foundation at Pfizer (NYSE: PFE).

Acticor is developing glenzocimab (ACT017), a humanized Antibody Fragment. The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI, and inhibits its action. Evidence of antithrombotic efficacy of glenzocimab and safety of inhibition of GPVI have been established both ex vivo and in vivo.

The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
Login
Username:

Password: